You just read:

U.S. District Court Orders FDA to Reconsider Application for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder

News provided by

Braeburn

Jul 23, 2019, 09:14 ET